Drug Combo Fails to Cut Fracture Risk in Brittle Bone Disease

(MedPage Today) — SEATTLE — Treating osteogenesis imperfecta with the parathyroid hormone teriparatide followed by zoledronic acid, a bisphosphonate, failed to reduce the risk of fractures compared with standard treatment, initial results of…